BLTE
Belite Bio, Inc
Biotechnology
Market Cap$4.96B
5Y Perf.+1362.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BLTE vs REPL
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$266M
5Y Perf.-75.7%
BLTE vs REPL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BLTE | REPL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.96B | $266M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-49M | $-315M |
| Total Debt | $537K | $76M |
| Cash & Equiv. | $32M | $111M |
BLTE vs REPL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BLTE
REPL
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 100 | 1462.5 | +1362.5% |
| Replimune Group, In… (REPL) | 100 | 24.3 | -75.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BLTE vs REPL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BLTE leads in 4 of 5 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BLTE
Belite Bio, Inc
The Income Pick
BLTE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.80
- 13.7% 10Y total return vs REPL's -78.0%
- Lower volatility, beta 0.80, Low D/E 0.4%, current ratio 24.31x
Best for: income & stability and long-term compounding
REPL
Replimune Group, Inc.
The Growth Play
REPL is the clearest fit if your priority is growth exposure.
- EPS growth 5.2%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | BLTE | 2.4% margin vs REPL's 2.4% |
| Stability / Safety | BLTE | Beta 0.80 vs REPL's 0.83, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BLTE | +154.4% vs REPL's -53.4% |
| Efficiency (ROA) | BLTE | -33.6% ROA vs REPL's -94.4%, ROIC -50.9% vs -51.9% |
BLTE vs REPL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBLTELAGGINGREPL
REPLReplimune Group, Inc.
1leads
BLTEBelite Bio, Inc
3leads
6 Total Categories
CATEGORYLEADERvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REPL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BLTE7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BLTE6/6
Risk & VolatilityBeta, volatility, and downside exposure
BLTE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REPL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BLTE and REPL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$50M | -$323M |
| Net IncomeAfter-tax profit | -$49M | -$315M |
| Free Cash FlowCash after capex | $0 | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -61.3% | +2.5% |
REPL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BLTE and REPL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| Market CapShares × price | $5.0B | $266M |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $231M |
| Trailing P/EPrice ÷ TTM EPS | -132.20x | -1.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 32.67x | 0.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BLTE and REPL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BLTE leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BLTE delivers a -34.9% return on equity — every $100 of shareholder capital generates $-35 in annual profit, vs $-150 for REPL. BLTE carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REPL's 0.18x. On the Piotroski fundamental quality scale (0–9), BLTE scores 3/9 vs REPL's 2/9, reflecting mixed financial health.
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| ROE (TTM)Return on equity | -34.9% | -149.5% |
| ROA (TTM)Return on assets | -33.6% | -94.4% |
| ROICReturn on invested capital | -50.9% | -51.9% |
| ROCEReturn on capital employed | -33.7% | -55.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.18x |
| Net DebtTotal debt minus cash | -$31M | -$35M |
| Cash & Equiv.Liquid assets | $32M | $111M |
| Total DebtShort + long-term debt | $537,000 | $76M |
| Interest CoverageEBIT ÷ Interest expense | -1999.80x | -48.62x |
BLTE leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BLTE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLTE five years ago would be worth $147,309 today (with dividends reinvested), compared to $932 for REPL. Over the past 12 months, BLTE leads with a +154.4% total return vs REPL's -53.4%. The 3-year compound annual growth rate (CAGR) favors BLTE at 79.9% vs REPL's -43.0% — a key indicator of consistent wealth creation.
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| YTD ReturnYear-to-date | -2.1% | -62.5% |
| 1-Year ReturnPast 12 months | +154.4% | -53.4% |
| 3-Year ReturnCumulative with dividends | +482.1% | -81.5% |
| 5-Year ReturnCumulative with dividends | +1373.1% | -90.7% |
| 10-Year ReturnCumulative with dividends | +1373.1% | -78.0% |
| CAGR (3Y)Annualised 3-year return | +79.9% | -43.0% |
BLTE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
BLTE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BLTE is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than REPL's 0.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BLTE currently trades 78.0% from its 52-week high vs REPL's 25.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.80x |
| 52-Week HighHighest price in past year | $200.00 | $13.24 |
| 52-Week LowLowest price in past year | $56.10 | $1.50 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +25.2% |
| RSI (14)Momentum oscillator 0–100 | 43.0 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 155K | 5.6M |
BLTE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BLTE as "Buy" and REPL as "Buy". Consensus price targets imply 274.3% upside for REPL (target: $13) vs 30.1% for BLTE (target: $203).
| Metric | BLTEBelite Bio, Inc | REPLReplimune Group, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $203.00 | $12.50 |
| # AnalystsCovering analysts | 6 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BLTE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). REPL leads in 1 (Income & Cash Flow). 1 tied.
Best OverallBelite Bio, Inc (BLTE)Leads 3 of 6 categories
Loading custom metrics...
BLTE vs REPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BLTE or REPL a better buy right now?
Analysts rate Belite Bio, Inc (BLTE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BLTE or REPL?
Over the past 5 years, Belite Bio, Inc (BLTE) delivered a total return of +1373%, compared to -90.
7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: BLTE returned +1363% versus REPL's -73. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BLTE or REPL?
By beta (market sensitivity over 5 years), Belite Bio, Inc (BLTE) is the lower-risk stock at 0.
79β versus Replimune Group, Inc. 's 0. 80β — meaning REPL is approximately 2% more volatile than BLTE relative to the S&P 500. On balance sheet safety, Belite Bio, Inc (BLTE) carries a lower debt/equity ratio of 0% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BLTE or REPL?
On earnings-per-share growth, the picture is similar: Replimune Group, Inc.
grew EPS 5. 2% year-over-year, compared to 0. 8% for Belite Bio, Inc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BLTE or REPL?
Belite Bio, Inc (BLTE) is the more profitable company, earning 0.
0% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BLTE leads at 0. 0% versus 0. 0% for REPL. At the gross margin level — before operating expenses — BLTE leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BLTE or REPL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BLTE or REPL better for a retirement portfolio?
For long-horizon retirement investors, Belite Bio, Inc (BLTE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
79), +1363% 10Y return). Both have compounded well over 10 years (BLTE: +1363%, REPL: -73. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BLTE and REPL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.